Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel‐group, phase I study in healthy subjects
British Journal of Clinical Pharmacology2016Vol. 83(5), pp. 1011–1027
Citations Over TimeTop 13% of 2016 papers
Tomohiko Harada, Darren Wilbraham, Guillemette de La Borderie, Shinsuke Inoue, Jim Bush, A. John Camm
Abstract
The study demonstrated a more favourable cardiac safety profile for amiselimod than fingolimod when administered over 28 days in healthy subjects.
Related Papers
- → Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy(2011)109 cited
- → Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions(2011)69 cited
- → Fingolimod Therapy for Multiple Sclerosis(2013)46 cited
- → Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod(2015)4 cited
- → High expression of cytotoxic molecules and Th1 bias of circulating T cells in patients with multiple sclerosis under fingolimod treatment(2014)